Orchestra BioMed snaps up full enrolment in Medtronic's BACKBEAT trial
Orchestra BioMed has surpassed its target of 316 patients in the pivotal BACKBEAT trial. Full enrollment positions the company to submit primary endpoint data in late 2027, supporting Medtronic's future FDA applications for AVIM Therapy.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed